 Gregory Kinney
Concepts (449)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pulmonary Disease, Chronic Obstructive | 61 | 2025 | 1042 | 6.260 |
Why?
| | Coronary Artery Disease | 28 | 2025 | 703 | 1.910 |
Why?
| | Smoking | 30 | 2025 | 1634 | 1.900 |
Why?
| | Tomography, X-Ray Computed | 43 | 2025 | 2679 | 1.810 |
Why?
| | Smokers | 18 | 2025 | 148 | 1.730 |
Why?
| | Diabetes Mellitus, Type 1 | 38 | 2025 | 3710 | 1.570 |
Why?
| | Pulmonary Emphysema | 14 | 2025 | 290 | 1.550 |
Why?
| | Cannabis | 10 | 2025 | 493 | 1.430 |
Why?
| | Forced Expiratory Volume | 26 | 2025 | 532 | 1.220 |
Why?
| | Bronchiectasis | 7 | 2023 | 111 | 1.010 |
Why?
| | Calcinosis | 17 | 2015 | 235 | 0.990 |
Why?
| | Dronabinol | 4 | 2024 | 229 | 0.880 |
Why?
| | Respiratory Function Tests | 11 | 2021 | 596 | 0.840 |
Why?
| | Hyperlipidemias | 2 | 2023 | 120 | 0.830 |
Why?
| | Lung | 23 | 2025 | 4067 | 0.830 |
Why?
| | Spirometry | 16 | 2025 | 281 | 0.810 |
Why?
| | Diabetic Ketoacidosis | 3 | 2022 | 202 | 0.810 |
Why?
| | Cannabinoids | 5 | 2024 | 161 | 0.780 |
Why?
| | Marijuana Smoking | 3 | 2022 | 252 | 0.780 |
Why?
| | Cardiovascular System | 1 | 2023 | 139 | 0.760 |
Why?
| | Middle Aged | 95 | 2025 | 33310 | 0.760 |
Why?
| | Disease Progression | 27 | 2025 | 2752 | 0.740 |
Why?
| | Cardiovascular Diseases | 7 | 2024 | 2113 | 0.700 |
Why?
| | Diabetic Angiopathies | 11 | 2016 | 259 | 0.670 |
Why?
| | Volatilization | 1 | 2019 | 56 | 0.650 |
Why?
| | Female | 116 | 2025 | 73052 | 0.630 |
Why?
| | Nebulizers and Vaporizers | 1 | 2019 | 86 | 0.630 |
Why?
| | Risk Factors | 40 | 2025 | 10368 | 0.620 |
Why?
| | Male | 106 | 2025 | 67560 | 0.610 |
Why?
| | Humans | 141 | 2025 | 137294 | 0.600 |
Why?
| | Diabetes Mellitus, Type 2 | 5 | 2023 | 2516 | 0.600 |
Why?
| | Aged | 52 | 2025 | 23851 | 0.600 |
Why?
| | Coronary Vessels | 7 | 2021 | 246 | 0.550 |
Why?
| | Cohort Studies | 32 | 2025 | 5726 | 0.530 |
Why?
| | Marijuana Abuse | 1 | 2019 | 233 | 0.520 |
Why?
| | Prospective Studies | 30 | 2025 | 7595 | 0.500 |
Why?
| | Air Pollution | 1 | 2019 | 315 | 0.490 |
Why?
| | Vascular Calcification | 5 | 2019 | 108 | 0.490 |
Why?
| | Risk Assessment | 9 | 2024 | 3439 | 0.480 |
Why?
| | 1-Alkyl-2-acetylglycerophosphocholine Esterase | 2 | 2016 | 22 | 0.480 |
Why?
| | Genetic Predisposition to Disease | 11 | 2025 | 2419 | 0.470 |
Why?
| | Arthritis, Rheumatoid | 4 | 2025 | 1167 | 0.470 |
Why?
| | Cigarette Smoking | 3 | 2025 | 101 | 0.460 |
Why?
| | Adult | 57 | 2025 | 37724 | 0.440 |
Why?
| | Prenatal Exposure Delayed Effects | 3 | 2025 | 607 | 0.420 |
Why?
| | Depression | 5 | 2025 | 1408 | 0.420 |
Why?
| | Genome-Wide Association Study | 9 | 2025 | 1434 | 0.410 |
Why?
| | Vital Capacity | 8 | 2025 | 309 | 0.400 |
Why?
| | Cannabidiol | 2 | 2024 | 119 | 0.370 |
Why?
| | Pulmonary Artery | 5 | 2024 | 1084 | 0.370 |
Why?
| | Coronary Disease | 7 | 2010 | 385 | 0.360 |
Why?
| | Longitudinal Studies | 10 | 2024 | 2850 | 0.360 |
Why?
| | Biomarkers | 13 | 2025 | 4164 | 0.350 |
Why?
| | Atherosclerosis | 4 | 2023 | 415 | 0.350 |
Why?
| | Airway Obstruction | 2 | 2024 | 162 | 0.340 |
Why?
| | Emphysema | 2 | 2023 | 109 | 0.340 |
Why?
| | Prevalence | 13 | 2025 | 2715 | 0.330 |
Why?
| | Lung Diseases, Interstitial | 3 | 2025 | 634 | 0.320 |
Why?
| | Pectoralis Muscles | 3 | 2021 | 18 | 0.300 |
Why?
| | Marijuana Use | 3 | 2024 | 203 | 0.300 |
Why?
| | Lipoproteins | 3 | 2016 | 168 | 0.300 |
Why?
| | Albuminuria | 4 | 2016 | 185 | 0.290 |
Why?
| | Case-Control Studies | 15 | 2025 | 3546 | 0.290 |
Why?
| | Calcium | 7 | 2018 | 1198 | 0.290 |
Why?
| | Cross-Sectional Studies | 16 | 2025 | 5436 | 0.280 |
Why?
| | Severity of Illness Index | 15 | 2023 | 2836 | 0.280 |
Why?
| | Bronchi | 3 | 2022 | 260 | 0.270 |
Why?
| | Metformin | 2 | 2021 | 330 | 0.270 |
Why?
| | Predictive Value of Tests | 11 | 2019 | 2032 | 0.260 |
Why?
| | Anxiety | 3 | 2025 | 1036 | 0.260 |
Why?
| | Young Adult | 15 | 2023 | 13163 | 0.260 |
Why?
| | Body Mass Index | 11 | 2024 | 2373 | 0.250 |
Why?
| | Proportional Hazards Models | 6 | 2019 | 1260 | 0.250 |
Why?
| | Monitoring, Intraoperative | 3 | 2010 | 56 | 0.240 |
Why?
| | Polymorphism, Single Nucleotide | 6 | 2025 | 2195 | 0.240 |
Why?
| | Tandem Mass Spectrometry | 2 | 2019 | 532 | 0.240 |
Why?
| | Genomic Structural Variation | 1 | 2025 | 12 | 0.230 |
Why?
| | United States | 12 | 2024 | 14742 | 0.230 |
Why?
| | Quality of Life | 4 | 2021 | 2885 | 0.230 |
Why?
| | Pulmonary Diffusing Capacity | 3 | 2023 | 75 | 0.230 |
Why?
| | Hypnotics and Sedatives | 2 | 2019 | 199 | 0.230 |
Why?
| | Cause of Death | 2 | 2018 | 429 | 0.230 |
Why?
| | Lumbar Vertebrae | 3 | 2020 | 246 | 0.230 |
Why?
| | Antidepressive Agents | 3 | 2019 | 235 | 0.230 |
Why?
| | Plaque, Atherosclerotic | 2 | 2023 | 57 | 0.230 |
Why?
| | Adrenal Insufficiency | 1 | 2025 | 31 | 0.230 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 2 | 2021 | 201 | 0.230 |
Why?
| | Self Administration | 1 | 2025 | 123 | 0.230 |
Why?
| | Receptors, Antigen, B-Cell | 1 | 2025 | 130 | 0.220 |
Why?
| | Adrenergic beta-Antagonists | 2 | 2017 | 323 | 0.220 |
Why?
| | Renal Insufficiency | 2 | 2016 | 156 | 0.220 |
Why?
| | Birth Weight | 2 | 2024 | 515 | 0.220 |
Why?
| | Follow-Up Studies | 11 | 2022 | 5125 | 0.220 |
Why?
| | Aged, 80 and over | 10 | 2024 | 7607 | 0.220 |
Why?
| | Vaping | 1 | 2025 | 63 | 0.220 |
Why?
| | C-Peptide | 1 | 2025 | 163 | 0.220 |
Why?
| | Symptom Flare Up | 2 | 2021 | 41 | 0.210 |
Why?
| | Polysomnography | 1 | 2024 | 185 | 0.210 |
Why?
| | Dyspnea | 5 | 2024 | 252 | 0.200 |
Why?
| | Logistic Models | 12 | 2017 | 2071 | 0.200 |
Why?
| | Fibrinogen | 3 | 2014 | 168 | 0.200 |
Why?
| | Tomography, Emission-Computed | 1 | 2022 | 66 | 0.200 |
Why?
| | Multimorbidity | 1 | 2023 | 47 | 0.200 |
Why?
| | Artificial Intelligence | 2 | 2023 | 277 | 0.200 |
Why?
| | Hydrocortisone | 1 | 2025 | 323 | 0.200 |
Why?
| | Adiponectin | 4 | 2016 | 244 | 0.190 |
Why?
| | Propofol | 2 | 2021 | 73 | 0.190 |
Why?
| | Limit of Detection | 2 | 2019 | 86 | 0.190 |
Why?
| | Population Health | 1 | 2023 | 47 | 0.190 |
Why?
| | Organ Size | 5 | 2025 | 477 | 0.190 |
Why?
| | Phenotype | 6 | 2025 | 3202 | 0.190 |
Why?
| | Umbilical Cord | 2 | 2021 | 85 | 0.190 |
Why?
| | Ketosis | 1 | 2022 | 12 | 0.190 |
Why?
| | Cystatin C | 3 | 2011 | 65 | 0.190 |
Why?
| | Molecular Epidemiology | 2 | 2019 | 67 | 0.180 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2023 | 99 | 0.180 |
Why?
| | Neurodegenerative Diseases | 1 | 2023 | 136 | 0.180 |
Why?
| | Cholesterol | 4 | 2011 | 410 | 0.180 |
Why?
| | Protective Agents | 1 | 2021 | 41 | 0.180 |
Why?
| | Sarcopenia | 1 | 2022 | 82 | 0.180 |
Why?
| | Models, Genetic | 1 | 2024 | 607 | 0.180 |
Why?
| | Hand Strength | 2 | 2022 | 122 | 0.180 |
Why?
| | Hallucinogens | 1 | 2023 | 105 | 0.180 |
Why?
| | Self Report | 3 | 2021 | 826 | 0.170 |
Why?
| | Antirheumatic Agents | 1 | 2023 | 292 | 0.170 |
Why?
| | Angiotensin Receptor Antagonists | 1 | 2021 | 92 | 0.170 |
Why?
| | Proteome | 1 | 2025 | 472 | 0.170 |
Why?
| | Glucocorticoids | 1 | 2025 | 596 | 0.170 |
Why?
| | Muscular Atrophy | 1 | 2021 | 83 | 0.170 |
Why?
| | Foraminotomy | 1 | 2020 | 1 | 0.170 |
Why?
| | C-Reactive Protein | 2 | 2014 | 412 | 0.170 |
Why?
| | Paresthesia | 1 | 2020 | 15 | 0.160 |
Why?
| | 2-Propanol | 1 | 2019 | 21 | 0.160 |
Why?
| | Hepatitis C | 1 | 2023 | 265 | 0.160 |
Why?
| | Pulmonary Heart Disease | 1 | 2019 | 6 | 0.160 |
Why?
| | Lumbosacral Region | 1 | 2020 | 58 | 0.160 |
Why?
| | Foam Cells | 1 | 2019 | 18 | 0.160 |
Why?
| | Osteoporosis | 1 | 2022 | 243 | 0.160 |
Why?
| | Hyperostosis | 1 | 2019 | 5 | 0.160 |
Why?
| | Delirium | 1 | 2021 | 89 | 0.160 |
Why?
| | B-Lymphocytes | 1 | 2025 | 846 | 0.160 |
Why?
| | Genetic Markers | 2 | 2019 | 344 | 0.160 |
Why?
| | Calibration | 1 | 2019 | 146 | 0.160 |
Why?
| | Diabetic Nephropathies | 2 | 2016 | 294 | 0.160 |
Why?
| | Spectrometry, Mass, Electrospray Ionization | 1 | 2019 | 180 | 0.150 |
Why?
| | Carbon Monoxide | 1 | 2019 | 80 | 0.150 |
Why?
| | Regression Analysis | 6 | 2022 | 1028 | 0.150 |
Why?
| | Multifactorial Inheritance | 3 | 2025 | 174 | 0.150 |
Why?
| | Anti-Anxiety Agents | 1 | 2019 | 46 | 0.150 |
Why?
| | Diabetes Complications | 2 | 2010 | 226 | 0.150 |
Why?
| | Surface Properties | 1 | 2019 | 416 | 0.150 |
Why?
| | Blood Glucose | 6 | 2022 | 2182 | 0.150 |
Why?
| | Proteomics | 1 | 2025 | 1108 | 0.150 |
Why?
| | Adipose Tissue | 2 | 2017 | 630 | 0.150 |
Why?
| | Sleep | 1 | 2024 | 755 | 0.140 |
Why?
| | Drug Overdose | 1 | 2022 | 344 | 0.140 |
Why?
| | Heart Ventricles | 2 | 2020 | 792 | 0.140 |
Why?
| | Insulin Resistance | 4 | 2017 | 1203 | 0.140 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 2019 | 194 | 0.140 |
Why?
| | Factor Analysis, Statistical | 1 | 2018 | 286 | 0.140 |
Why?
| | Idiopathic Pulmonary Fibrosis | 1 | 2025 | 653 | 0.140 |
Why?
| | Vascular Remodeling | 1 | 2019 | 189 | 0.140 |
Why?
| | Polymorphism, Genetic | 3 | 2011 | 658 | 0.140 |
Why?
| | Urine | 1 | 2017 | 56 | 0.140 |
Why?
| | Linear Models | 6 | 2019 | 846 | 0.140 |
Why?
| | Population Surveillance | 1 | 2021 | 473 | 0.140 |
Why?
| | Sexual and Gender Minorities | 1 | 2021 | 214 | 0.140 |
Why?
| | HIV Infections | 2 | 2023 | 2820 | 0.130 |
Why?
| | Environmental Monitoring | 1 | 2019 | 369 | 0.130 |
Why?
| | Evoked Potentials, Somatosensory | 3 | 2015 | 33 | 0.130 |
Why?
| | Chronic Disease | 1 | 2023 | 1788 | 0.130 |
Why?
| | Growth Differentiation Factor 15 | 1 | 2017 | 41 | 0.130 |
Why?
| | Lung Diseases | 1 | 2023 | 769 | 0.130 |
Why?
| | Bronchitis, Chronic | 1 | 2016 | 25 | 0.130 |
Why?
| | Obesity | 4 | 2022 | 2983 | 0.130 |
Why?
| | Prenatal Care | 1 | 2019 | 288 | 0.130 |
Why?
| | Blood Pressure | 5 | 2023 | 1776 | 0.120 |
Why?
| | Plasma | 1 | 2017 | 213 | 0.120 |
Why?
| | Aortography | 1 | 2015 | 52 | 0.120 |
Why?
| | Intraoperative Neurophysiological Monitoring | 1 | 2015 | 21 | 0.120 |
Why?
| | Comorbidity | 5 | 2021 | 1624 | 0.120 |
Why?
| | Multivariate Analysis | 5 | 2019 | 1521 | 0.120 |
Why?
| | Dexmedetomidine | 1 | 2015 | 44 | 0.120 |
Why?
| | Respiratory System | 1 | 2016 | 157 | 0.120 |
Why?
| | Spinal Fusion | 3 | 2020 | 251 | 0.120 |
Why?
| | Periodontal Diseases | 1 | 2015 | 60 | 0.110 |
Why?
| | Evoked Potentials, Motor | 2 | 2015 | 50 | 0.110 |
Why?
| | Adiposity | 2 | 2022 | 518 | 0.110 |
Why?
| | Respiratory Muscles | 1 | 2014 | 33 | 0.110 |
Why?
| | Machine Learning | 1 | 2019 | 491 | 0.110 |
Why?
| | Exercise Tolerance | 3 | 2023 | 279 | 0.110 |
Why?
| | Endothelium, Vascular | 1 | 2021 | 927 | 0.110 |
Why?
| | Evoked Potentials | 1 | 2015 | 126 | 0.110 |
Why?
| | Sex Factors | 5 | 2025 | 2073 | 0.110 |
Why?
| | Health Status | 2 | 2022 | 789 | 0.110 |
Why?
| | Polycystic Ovary Syndrome | 1 | 2017 | 176 | 0.110 |
Why?
| | Body Composition | 4 | 2021 | 678 | 0.110 |
Why?
| | Subcutaneous Fat | 1 | 2014 | 81 | 0.110 |
Why?
| | Heart | 1 | 2017 | 657 | 0.110 |
Why?
| | Haplotypes | 2 | 2025 | 493 | 0.110 |
Why?
| | Spine | 1 | 2015 | 173 | 0.110 |
Why?
| | Pregnancy Complications | 1 | 2019 | 525 | 0.110 |
Why?
| | Brain | 1 | 2025 | 2675 | 0.100 |
Why?
| | Up-Regulation | 1 | 2016 | 844 | 0.100 |
Why?
| | Pregnancy | 5 | 2025 | 6743 | 0.100 |
Why?
| | Sex Distribution | 5 | 2014 | 376 | 0.100 |
Why?
| | Aorta | 1 | 2015 | 417 | 0.100 |
Why?
| | Orthopedic Procedures | 1 | 2015 | 221 | 0.100 |
Why?
| | Incidence | 4 | 2024 | 2808 | 0.100 |
Why?
| | Colorado | 6 | 2021 | 4527 | 0.100 |
Why?
| | Prognosis | 5 | 2024 | 4026 | 0.100 |
Why?
| | Surveys and Questionnaires | 8 | 2025 | 5769 | 0.090 |
Why?
| | Blood Vessels | 1 | 2013 | 187 | 0.090 |
Why?
| | Time Factors | 7 | 2024 | 6818 | 0.090 |
Why?
| | Triglycerides | 2 | 2011 | 524 | 0.090 |
Why?
| | Haptoglobins | 1 | 2011 | 53 | 0.090 |
Why?
| | Imaging, Three-Dimensional | 1 | 2015 | 577 | 0.090 |
Why?
| | Registries | 1 | 2019 | 2016 | 0.090 |
Why?
| | Reference Values | 4 | 2023 | 818 | 0.090 |
Why?
| | Hypertension, Pulmonary | 1 | 2022 | 1904 | 0.090 |
Why?
| | Radiography | 4 | 2016 | 832 | 0.090 |
Why?
| | Occupational Exposure | 1 | 2014 | 338 | 0.090 |
Why?
| | Genotype | 4 | 2024 | 1923 | 0.090 |
Why?
| | Electrodiagnosis | 1 | 2010 | 17 | 0.080 |
Why?
| | Adolescent | 6 | 2022 | 21499 | 0.080 |
Why?
| | Carotid Intima-Media Thickness | 2 | 2023 | 91 | 0.080 |
Why?
| | Walk Test | 2 | 2021 | 76 | 0.080 |
Why?
| | Diagnostic Techniques, Neurological | 1 | 2009 | 11 | 0.080 |
Why?
| | Statistics, Nonparametric | 1 | 2011 | 431 | 0.080 |
Why?
| | Coma | 1 | 2009 | 32 | 0.080 |
Why?
| | Iliac Artery | 1 | 2010 | 55 | 0.080 |
Why?
| | Patient Education as Topic | 2 | 2005 | 762 | 0.080 |
Why?
| | Anesthesia, General | 2 | 2021 | 73 | 0.080 |
Why?
| | Meningomyelocele | 1 | 2010 | 59 | 0.080 |
Why?
| | Alcohol Drinking | 2 | 2009 | 821 | 0.080 |
Why?
| | Pediatric Obesity | 1 | 2017 | 590 | 0.080 |
Why?
| | Facial Nerve | 1 | 2009 | 38 | 0.080 |
Why?
| | Lymphatic Abnormalities | 1 | 2009 | 19 | 0.080 |
Why?
| | Aortic Diseases | 1 | 2010 | 117 | 0.080 |
Why?
| | Hypoxia-Ischemia, Brain | 1 | 2009 | 37 | 0.080 |
Why?
| | Uric Acid | 1 | 2010 | 163 | 0.080 |
Why?
| | Respiratory Physiological Phenomena | 2 | 2022 | 31 | 0.080 |
Why?
| | Retrospective Studies | 8 | 2021 | 15639 | 0.080 |
Why?
| | Sensitivity and Specificity | 3 | 2022 | 1946 | 0.080 |
Why?
| | Hypertension | 5 | 2015 | 1285 | 0.080 |
Why?
| | Intraoperative Complications | 1 | 2010 | 138 | 0.080 |
Why?
| | Diet, Ketogenic | 1 | 2009 | 37 | 0.080 |
Why?
| | Airway Remodeling | 2 | 2021 | 64 | 0.080 |
Why?
| | Asymptomatic Diseases | 2 | 2021 | 89 | 0.070 |
Why?
| | Odds Ratio | 4 | 2014 | 1067 | 0.070 |
Why?
| | Anesthesia, Intravenous | 2 | 2021 | 16 | 0.070 |
Why?
| | Proteinuria | 1 | 2009 | 97 | 0.070 |
Why?
| | Reproducibility of Results | 5 | 2017 | 3283 | 0.070 |
Why?
| | Neurosurgical Procedures | 1 | 2010 | 197 | 0.070 |
Why?
| | Kidney | 1 | 2016 | 1467 | 0.070 |
Why?
| | Reproductive History | 1 | 2008 | 17 | 0.070 |
Why?
| | Aorta, Thoracic | 1 | 2010 | 267 | 0.070 |
Why?
| | Coronary Angiography | 2 | 2014 | 312 | 0.070 |
Why?
| | Angiotensin II Type 2 Receptor Blockers | 1 | 2007 | 7 | 0.070 |
Why?
| | Face | 1 | 2009 | 173 | 0.070 |
Why?
| | Cystatins | 1 | 2007 | 7 | 0.070 |
Why?
| | Spinal Cord | 1 | 2010 | 370 | 0.070 |
Why?
| | Asthma | 1 | 2021 | 2293 | 0.070 |
Why?
| | Age of Onset | 2 | 2025 | 519 | 0.070 |
Why?
| | Dietary Fats | 1 | 2009 | 304 | 0.070 |
Why?
| | Inflammation | 2 | 2021 | 2836 | 0.070 |
Why?
| | Life Style | 1 | 2009 | 488 | 0.070 |
Why?
| | Heart Rate | 1 | 2010 | 823 | 0.060 |
Why?
| | Renin-Angiotensin System | 1 | 2007 | 84 | 0.060 |
Why?
| | Apolipoproteins A | 1 | 2006 | 19 | 0.060 |
Why?
| | Apolipoproteins C | 1 | 2006 | 4 | 0.060 |
Why?
| | Kidney Diseases | 1 | 2010 | 406 | 0.060 |
Why?
| | Mortality | 2 | 2019 | 361 | 0.060 |
Why?
| | Contraception | 1 | 2008 | 162 | 0.060 |
Why?
| | Child, Preschool | 4 | 2024 | 11080 | 0.060 |
Why?
| | Propensity Score | 2 | 2019 | 290 | 0.060 |
Why?
| | Infant, Newborn | 3 | 2025 | 6054 | 0.060 |
Why?
| | Receptors, Interleukin-2 | 1 | 2005 | 66 | 0.060 |
Why?
| | Cluster Analysis | 2 | 2019 | 497 | 0.060 |
Why?
| | Internationality | 2 | 2017 | 155 | 0.060 |
Why?
| | Receptors, IgG | 1 | 2005 | 75 | 0.060 |
Why?
| | Chi-Square Distribution | 3 | 2010 | 533 | 0.060 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2010 | 443 | 0.060 |
Why?
| | Immunoglobulin Heavy Chains | 1 | 2025 | 83 | 0.060 |
Why?
| | Chromosomes, Human, Pair 6 | 1 | 2025 | 54 | 0.060 |
Why?
| | Abdominal Wall | 1 | 2004 | 24 | 0.060 |
Why?
| | Antihypertensive Agents | 2 | 2007 | 488 | 0.060 |
Why?
| | Protein Interaction Maps | 1 | 2024 | 48 | 0.060 |
Why?
| | Drug Repositioning | 1 | 2024 | 35 | 0.060 |
Why?
| | Pandemics | 2 | 2024 | 1623 | 0.060 |
Why?
| | Apolipoprotein C-III | 2 | 2019 | 12 | 0.060 |
Why?
| | Whole Genome Sequencing | 1 | 2025 | 153 | 0.050 |
Why?
| | Amygdala | 1 | 2025 | 191 | 0.050 |
Why?
| | Laryngeal Nerves | 1 | 2023 | 7 | 0.050 |
Why?
| | Laryngeal Muscles | 1 | 2023 | 12 | 0.050 |
Why?
| | HLA Antigens | 1 | 2025 | 237 | 0.050 |
Why?
| | Reflex | 1 | 2023 | 68 | 0.050 |
Why?
| | United Kingdom | 1 | 2024 | 315 | 0.050 |
Why?
| | Glomerular Filtration Rate | 3 | 2016 | 745 | 0.050 |
Why?
| | Glucose Clamp Technique | 2 | 2017 | 195 | 0.050 |
Why?
| | Infant | 3 | 2025 | 9451 | 0.050 |
Why?
| | Cholesterol, LDL | 1 | 2005 | 366 | 0.050 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2005 | 382 | 0.050 |
Why?
| | Antigens, CD | 1 | 2005 | 522 | 0.050 |
Why?
| | Nutrition Surveys | 1 | 2024 | 267 | 0.050 |
Why?
| | Insulin | 3 | 2022 | 2406 | 0.050 |
Why?
| | Herpesvirus 4, Human | 1 | 2023 | 167 | 0.050 |
Why?
| | Blood Platelets | 1 | 2005 | 407 | 0.050 |
Why?
| | Radiography, Thoracic | 2 | 2014 | 168 | 0.050 |
Why?
| | Morbidity | 1 | 2022 | 324 | 0.050 |
Why?
| | Muscles | 1 | 2022 | 325 | 0.050 |
Why?
| | Lung Volume Measurements | 1 | 2021 | 46 | 0.040 |
Why?
| | Survival Analysis | 2 | 2017 | 1321 | 0.040 |
Why?
| | Biological Variation, Population | 1 | 2021 | 21 | 0.040 |
Why?
| | Reaction Time | 2 | 2015 | 416 | 0.040 |
Why?
| | Protective Factors | 1 | 2021 | 93 | 0.040 |
Why?
| | Plethysmography | 1 | 2021 | 106 | 0.040 |
Why?
| | Hepacivirus | 1 | 2023 | 259 | 0.040 |
Why?
| | Adrenergic beta-2 Receptor Agonists | 1 | 2021 | 37 | 0.040 |
Why?
| | Breast Feeding | 1 | 2024 | 439 | 0.040 |
Why?
| | Hospitals, Urban | 1 | 2021 | 134 | 0.040 |
Why?
| | Diskectomy, Percutaneous | 1 | 2020 | 1 | 0.040 |
Why?
| | Substance Abuse Detection | 1 | 2021 | 89 | 0.040 |
Why?
| | Bayes Theorem | 1 | 2022 | 401 | 0.040 |
Why?
| | Diabetes Mellitus | 1 | 2009 | 1036 | 0.040 |
Why?
| | Diskectomy | 1 | 2020 | 23 | 0.040 |
Why?
| | Child Development | 1 | 2024 | 471 | 0.040 |
Why?
| | Hippocampus | 1 | 2025 | 895 | 0.040 |
Why?
| | Models, Statistical | 1 | 2024 | 670 | 0.040 |
Why?
| | Homosexuality, Male | 1 | 2021 | 184 | 0.040 |
Why?
| | Hospitals, Pediatric | 2 | 2017 | 533 | 0.040 |
Why?
| | Oligodeoxyribonucleotides, Antisense | 1 | 2019 | 8 | 0.040 |
Why?
| | rab4 GTP-Binding Proteins | 1 | 2019 | 9 | 0.040 |
Why?
| | Computer Simulation | 1 | 2024 | 979 | 0.040 |
Why?
| | Cytochrome P-450 CYP2B6 | 1 | 2019 | 9 | 0.040 |
Why?
| | Cytochrome P450 Family 2 | 1 | 2019 | 12 | 0.040 |
Why?
| | Analysis of Variance | 2 | 2014 | 1318 | 0.040 |
Why?
| | Bronchodilator Agents | 1 | 2021 | 248 | 0.040 |
Why?
| | Treatment Outcome | 3 | 2021 | 10800 | 0.040 |
Why?
| | Proof of Concept Study | 1 | 2019 | 79 | 0.040 |
Why?
| | Aryl Hydrocarbon Hydroxylases | 1 | 2019 | 48 | 0.040 |
Why?
| | Administration, Inhalation | 1 | 2021 | 683 | 0.040 |
Why?
| | Multidetector Computed Tomography | 1 | 2019 | 39 | 0.040 |
Why?
| | RNA, Viral | 1 | 2023 | 654 | 0.040 |
Why?
| | Genetic Variation | 1 | 2024 | 988 | 0.040 |
Why?
| | Lipids | 2 | 2017 | 666 | 0.040 |
Why?
| | Bone Density | 1 | 2022 | 487 | 0.040 |
Why?
| | Genomics | 1 | 2023 | 792 | 0.040 |
Why?
| | Europe | 1 | 2019 | 414 | 0.040 |
Why?
| | Electroencephalography | 1 | 2021 | 433 | 0.040 |
Why?
| | Systems Biology | 1 | 2018 | 66 | 0.040 |
Why?
| | Rats, Sprague-Dawley | 1 | 2023 | 2486 | 0.040 |
Why?
| | Atmospheric Pressure | 1 | 2017 | 23 | 0.040 |
Why?
| | Drug Therapy, Combination | 1 | 2021 | 1063 | 0.040 |
Why?
| | Exercise | 1 | 2009 | 2045 | 0.040 |
Why?
| | Electric Impedance | 1 | 2017 | 107 | 0.030 |
Why?
| | Gene Expression Profiling | 1 | 2024 | 1774 | 0.030 |
Why?
| | Electrocardiography | 2 | 2010 | 630 | 0.030 |
Why?
| | Maternal Health Services | 1 | 2019 | 97 | 0.030 |
Why?
| | Endoscopy | 1 | 2020 | 318 | 0.030 |
Why?
| | Adrenal Cortex Hormones | 1 | 2021 | 556 | 0.030 |
Why?
| | Total Lung Capacity | 1 | 2016 | 33 | 0.030 |
Why?
| | Diagnostic Imaging | 1 | 2019 | 331 | 0.030 |
Why?
| | Michigan | 1 | 2017 | 108 | 0.030 |
Why?
| | Glucose | 1 | 2022 | 1028 | 0.030 |
Why?
| | Bronchial Arteries | 1 | 2016 | 12 | 0.030 |
Why?
| | Causality | 1 | 2017 | 127 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2018 | 892 | 0.030 |
Why?
| | RNA | 1 | 2023 | 924 | 0.030 |
Why?
| | Area Under Curve | 1 | 2016 | 315 | 0.030 |
Why?
| | Urban Population | 1 | 2019 | 475 | 0.030 |
Why?
| | Evoked Potentials, Visual | 1 | 2015 | 35 | 0.030 |
Why?
| | Statistics as Topic | 1 | 2016 | 313 | 0.030 |
Why?
| | Anesthetics, Intravenous | 1 | 2015 | 47 | 0.030 |
Why?
| | Cough | 1 | 2016 | 121 | 0.030 |
Why?
| | Automation | 1 | 2015 | 95 | 0.030 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2017 | 597 | 0.030 |
Why?
| | Muscle Strength | 1 | 2018 | 317 | 0.030 |
Why?
| | Cognition | 1 | 2023 | 1169 | 0.030 |
Why?
| | Animals | 3 | 2023 | 36862 | 0.030 |
Why?
| | ROC Curve | 1 | 2016 | 548 | 0.030 |
Why?
| | Physical Endurance | 1 | 2016 | 277 | 0.030 |
Why?
| | Rats | 1 | 2023 | 5639 | 0.030 |
Why?
| | Sex Characteristics | 2 | 2014 | 765 | 0.030 |
Why?
| | Gastroesophageal Reflux | 1 | 2017 | 234 | 0.030 |
Why?
| | Child | 3 | 2025 | 21999 | 0.030 |
Why?
| | Stroke | 1 | 2003 | 1134 | 0.030 |
Why?
| | Inflammation Mediators | 1 | 2017 | 514 | 0.030 |
Why?
| | Piperidines | 1 | 2015 | 206 | 0.030 |
Why?
| | Dyslipidemias | 1 | 2015 | 176 | 0.030 |
Why?
| | Hypercholesterolemia | 1 | 2014 | 105 | 0.030 |
Why?
| | Magnetic Resonance Imaging | 1 | 2025 | 3568 | 0.030 |
Why?
| | Mice | 2 | 2021 | 17774 | 0.030 |
Why?
| | Angiography | 1 | 2013 | 207 | 0.020 |
Why?
| | Quality Improvement | 1 | 2021 | 1172 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2019 | 3009 | 0.020 |
Why?
| | Vascular Stiffness | 1 | 2017 | 493 | 0.020 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2011 | 345 | 0.020 |
Why?
| | Exercise Test | 1 | 2014 | 625 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2021 | 5753 | 0.020 |
Why?
| | Double-Blind Method | 1 | 2015 | 1985 | 0.020 |
Why?
| | Laminectomy | 1 | 2010 | 31 | 0.020 |
Why?
| | Gene Frequency | 1 | 2011 | 521 | 0.020 |
Why?
| | Pyramidal Tracts | 1 | 2010 | 31 | 0.020 |
Why?
| | Radiographic Image Interpretation, Computer-Assisted | 1 | 2010 | 107 | 0.020 |
Why?
| | Internal Fixators | 1 | 2010 | 36 | 0.020 |
Why?
| | Thoracic Vertebrae | 1 | 2010 | 77 | 0.020 |
Why?
| | Median Nerve | 1 | 2009 | 24 | 0.020 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2016 | 612 | 0.020 |
Why?
| | Neural Tube Defects | 1 | 2010 | 63 | 0.020 |
Why?
| | Intra-Abdominal Fat | 1 | 2010 | 91 | 0.020 |
Why?
| | Facial Paralysis | 1 | 2009 | 22 | 0.020 |
Why?
| | Functional Laterality | 1 | 2010 | 224 | 0.020 |
Why?
| | Artifacts | 1 | 2009 | 129 | 0.020 |
Why?
| | Observer Variation | 1 | 2009 | 345 | 0.020 |
Why?
| | Personality Inventory | 1 | 2009 | 141 | 0.020 |
Why?
| | Chromatography, Liquid | 1 | 2010 | 432 | 0.020 |
Why?
| | Diabetic Neuropathies | 1 | 2009 | 93 | 0.020 |
Why?
| | Age Factors | 2 | 2007 | 3297 | 0.020 |
Why?
| | Postoperative Complications | 2 | 2010 | 2658 | 0.020 |
Why?
| | Algorithms | 1 | 2015 | 1692 | 0.020 |
Why?
| | Scoliosis | 1 | 2010 | 215 | 0.020 |
Why?
| | Health Surveys | 1 | 2009 | 517 | 0.020 |
Why?
| | Angiotensins | 1 | 2007 | 9 | 0.020 |
Why?
| | Receptor, Angiotensin, Type 1 | 1 | 2007 | 25 | 0.020 |
Why?
| | Peptidyl-Dipeptidase A | 1 | 2007 | 52 | 0.020 |
Why?
| | Electromyography | 1 | 2009 | 401 | 0.020 |
Why?
| | Contraceptive Agents, Female | 1 | 2008 | 80 | 0.020 |
Why?
| | Preoperative Care | 1 | 2009 | 358 | 0.020 |
Why?
| | Diabetic Retinopathy | 1 | 2009 | 189 | 0.020 |
Why?
| | Patient Selection | 1 | 2010 | 692 | 0.020 |
Why?
| | Self Care | 1 | 2009 | 375 | 0.020 |
Why?
| | Amino Acid Substitution | 1 | 2006 | 309 | 0.010 |
Why?
| | Waist-Hip Ratio | 1 | 2004 | 39 | 0.010 |
Why?
| | Platelet Aggregation | 1 | 2005 | 100 | 0.010 |
Why?
| | Radiography, Abdominal | 1 | 2004 | 45 | 0.010 |
Why?
| | Age Distribution | 1 | 2005 | 391 | 0.010 |
Why?
| | Hospitalization | 1 | 2014 | 2214 | 0.010 |
Why?
| | Anthropometry | 1 | 2004 | 213 | 0.010 |
Why?
| | Feeding Behavior | 1 | 2009 | 648 | 0.010 |
Why?
| | Alleles | 1 | 2006 | 892 | 0.010 |
Why?
| | Flow Cytometry | 1 | 2005 | 1184 | 0.010 |
Why?
| | Promoter Regions, Genetic | 1 | 2006 | 1250 | 0.010 |
Why?
| | Neoplasms | 1 | 2016 | 2661 | 0.010 |
Why?
| | Risk | 1 | 2003 | 908 | 0.010 |
Why?
| | Hyperglycemia | 1 | 2003 | 347 | 0.010 |
Why?
| | Oxidative Stress | 1 | 2006 | 1315 | 0.010 |
Why?
| | DNA | 1 | 2006 | 1459 | 0.010 |
Why?
| | Hypoglycemic Agents | 1 | 2005 | 1283 | 0.010 |
Why?
|
|
Kinney's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|